Cholinergic Drugs for Alzheimer's Disease

Cholinergic Drugs for Alzheimer’s Disease: From Central Cholinergic Neurotransmission to Drug Therapies and Natural Products with Multitarget Actions addresses the urgent need for advanced resources in neuropharmacology. As Alzheimer’s Disease continues to impact an aging global population, the complexity of neurodegenerative mechanisms necessitates comprehensive scientific references. This book responds to the increasing demand for detailed knowledge on cholinergic neurotransmission, acetylcholinesterase inhibitors, and emerging therapeutic strategies, bridging foundational theory and translational applications for researchers, clinicians, and students. The reference is organized into three major sections. The first section presents mechanistic insights into cholinergic drugs, current hypotheses for Alzheimer’s Disease progression, neurotransmitter systems, receptor biology, and the evolution of acetylcholinesterase inhibitors, including hybrid and multi-target drugs. It also covers clinical status, neuromuscular blockers, non-adrenergic neurotransmitters, protein kinase inhibitors, inflammation modulation, NMDA antagonism, biomarkers, and AI-assisted drug discovery. The second section explores natural alkaloidal and non-alkaloidal compounds, molecular docking, SAR analysis, and daily consumable resources. The third section investigates marine-derived AChE inhibitors, dual- and multi-target drug concepts, and emerging therapeutic compounds. Cholinergic Drugs for Alzheimer’s Disease equips the scientific community with a robust foundation for understanding and innovating in Alzheimer’s Disease therapy. By integrating molecular biology, pharmacology, and computational approaches, the book empowers researchers and clinicians to address treatment challenges, optimize drug design, and leverage natural products for multifactorial intervention.